Premium
Idelalisib‐rituximab induces durable remissions in TP53 disrupted B‐PLL but results in significant toxicity: updated results of the UK‐wide compassionate use programme
Author(s) -
Eyre Toby A.,
Fox Christopher P.,
Boden Ali,
Bloor Adrian,
Dungawalla Moez,
Shankara Paneesha,
Went Richard,
Schuh Anna H.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15151
Subject(s) - idelalisib , compassionate use , toxicity , rituximab , medicine , ibrutinib , oncology , lymphoma , leukemia , clinical trial , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom